Trials / Completed
CompletedNCT02875743
King's Invasive Aspergillosis Study II
Incidence of Invasive Fungal Disease in Patients Receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole Prophylaxis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- King's College Hospital NHS Trust · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Invasive fungal disease (IFD) is an important cause of mortality and morbidity in patients undergoing intensive chemotherapy or transplantation. This current study aims to assess the impact of prophylactically using the broad-spectrum anti-fungal agent posaconazole on the incidence of IFD in high risk patients with aplastic anaemia and those undergoing intensive chemotherapy, for example for acute myeloid leukaemia, and allogeneic stem cell transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Posaconazole |
Timeline
- Start date
- 2016-12-07
- Primary completion
- 2018-10-31
- Completion
- 2019-10-31
- First posted
- 2016-08-23
- Last updated
- 2020-04-02
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02875743. Inclusion in this directory is not an endorsement.